You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,871,732


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,871,732
Title:Immunostimulatory sequence oligonucleotides and methods of using the same
Abstract: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
Inventor(s): Dina; Dino (Oakland, CA), Fearon; Karen L. (Lafayette, CA), Marshall; Jason (Oakland, CA)
Assignee: Dynavax Technologies Corporation (Berkeley, CA)
Application Number:13/438,757
Patent Claims:1. A method of modulating an immune response in a mammal comprising: administering to a mammal an immunomodulatory polynucleotide (IMP) in an amount sufficient to modulate an immune response in said-mammal, wherein said IMP comprises: TABLE-US-00044 (SEQ ID NO: 156) a) 5'-N.sub.x(TCG(N.sub.q)).sub.yN.sub.w(X.sub.1X.sub.2CGX.sub.2'X.sub.1'- CG).sub.p).sub.z

wherein N are nucleosides, x=0-3, y=1-4, w=-2, -1, 0, 1 or 2, p=0 or 1, q=0, 1 or 2, and z=1-20, X.sub.1 and X.sub.1' are self-complimentary nucleosides, X.sub.2 and X.sub.2' are self-complimentary nucleosides, and wherein the 5' T of the (TCG(N.sub.q)).sub.y sequence is 0-3 bases from the 5' end of the polynucleotide; and b) a palindromic sequence at least 8 bases in length wherein the palindromic sequence comprises the first (X.sub.1X.sub.2CGX.sub.2'X.sub.1') of the (X.sub.1X.sub.2CGX.sub.2'X.sub.1'(CG).sub.p).sub.z sequences, and wherein the mammal has cancer.

2. The method of to claim 1 wherein the IMP comprises a sequence selected from the group consisting of SEQ ID NO: 172, SEQ ID NO: 55, SEQ ID NO: 113, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 53, SEQ ID NO: 109, SEQ ID NO: 117, SEQ ID NO: 175, SEQ ID NO: 45, SEQ ID NO: 75, and SEQ ID NO: 44.

3. The method of claim 1 wherein the mammal is receiving a vaccine.

4. The method of claim 3 wherein the vaccine is a prophylactic vaccine.

5. The method of claim 3 wherein the vaccine is a therapeutic vaccine.

6. The method of claim 5 wherein the therapeutic vaccine comprises tumor associated antigens and/or tumor cells from a mammal with cancer.

7. The method of claim 1 wherein the method further comprises administration of one or more additional therapeutic agents.

8. The method of claim 7 wherein the one or more additional therapeutic agents is selected from the group consisting of: anti-tumor antibodies, chemotherapy regimens and radiation treatments.

9. The method of claim 8 wherein the anti-tumor antibodies are anti-tumor antibody fragments and/or derivatives thereof or monoclonal anti-tumor antibodies, fragments and/or derivatives thereof.

10. The method of claim 8 wherein the anti-tumor antibodies are rituximab or trastuzumab.

11. The method of claim 7 wherein therapeutic agent is an immunotherapeutic agent selected from the group consisting of cytokines, adjuvants, and antibodies.

12. The method of claim 1, wherein the IMP comprises SEQ ID NO: 172.

13. The method of any one of claims 1, 2 and 3-12, wherein the mammal is a human.

Details for Patent 8,871,732

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2022-12-23
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2022-12-23
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2022-12-23
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2022-12-23
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2022-12-23
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2022-12-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.